241 related articles for article (PubMed ID: 24787244)
1. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
[TBL] [Abstract][Full Text] [Related]
2. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
3. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
4. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
5. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
6. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
8. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
9. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
10. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.
Balyasnikova IV; Wainwright DA; Solomaha E; Lee G; Han Y; Thaci B; Lesniak MS
J Biol Chem; 2012 Aug; 287(36):30215-27. PubMed ID: 22778273
[TBL] [Abstract][Full Text] [Related]
11. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
12. Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis.
Brown CE; Warden CD; Starr R; Deng X; Badie B; Yuan YC; Forman SJ; Barish ME
PLoS One; 2013; 8(10):e77769. PubMed ID: 24204956
[TBL] [Abstract][Full Text] [Related]
13. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
15. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
16. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
[TBL] [Abstract][Full Text] [Related]
17. A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors.
Kim JW; Young JS; Solomaha E; Kanojia D; Lesniak MS; Balyasnikova IV
Sci Rep; 2015 Dec; 5():18133. PubMed ID: 26656559
[TBL] [Abstract][Full Text] [Related]
18. Induction of cytotoxic T lymphocytes specific to malignant glioma using T2 cells pulsed with HLA-A2-restricted interleukin-13 receptor alpha 2 peptide in vitro.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Acta Biochim Biophys Sin (Shanghai); 2007 Sep; 39(9):641-8. PubMed ID: 17805458
[TBL] [Abstract][Full Text] [Related]
19. An MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma.
Shi J; Hou S; Huang J; Wang S; Huan W; Huang C; Liu X; Jiang R; Qian W; Lu J; Wang X; Shi W; Huang R; Chen J
Nanoscale; 2017 Jul; 9(26):8970-8981. PubMed ID: 28443896
[TBL] [Abstract][Full Text] [Related]
20. A novel target anti-interleukin-13 receptor subunit alpha-2 monoclonal antibody inhibits tumor growth and metastasis in lung cancer.
Raza G; Yunus FU; Mangukiya HB; Merugu SB; Mashausi DS; Zeling W; Negi H; Zhou B; Roy D; Wu Z; Li D
Int Immunopharmacol; 2021 Jan; 90():107155. PubMed ID: 33243603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]